Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

3 Jun 2019 17:06

RNS Number : 9938A
Instem plc
03 June 2019
 

Instem plc("Instem" or the "Company")

Director/PDMR Shareholding

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, was notified on 3 June 2019, that Mike McGoun, a Non-Executive Director of the Company, sold 6,786 ordinary shares of 10p each in the Company ("Ordinary Shares") on 29 May 2019 at a price of 340 pence per Ordinary Share. Following the transaction, Mike holds no Ordinary Shares in the Company.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

Mike McGoun

 

2

Reason for the notification

a)

 

Position/status

Non Executive Director

b)

 

Initial notification /Amendment

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

 

Instem plc

b)

 

LEI

 

 

213800PILYUFNNROQX68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 10p each

Identification code

GB00B3TQCK30

b)

 

Nature of the transaction

Sale of ordinary shares

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

340p

6,786

d)

 

Aggregated information

- Aggregated volume

6,786

- Price

£23,072.40

e)

 

Date of the transaction

29 May 2019

f)

Place of the transaction

London Stock Exchange (XLON)

 

For further information, please contact:

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

 

N+1 Singer (Nominated Adviser & Broker)

 

+44 (0) 20 7496 3000

Richard Lindley

Rachel Hayes

 

Walbrook Financial PR

 

+44 (0) 20 7933 8780

Paul Cornelius

instem@walbrookpr.com

Nick Rome

Sam Allen

 

About Instem 

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

 Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

To learn more about Instem solutions and its mission, please visit instem.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBLGDLSGGBGCX
Date   Source Headline
15th May 20237:00 amRNSTransfer of ToxHub Platform and launch of Centrus®
11th May 20233:26 pmRNSHolding(s) in Company
11th May 20237:00 amRNSUS Government Contract Award
4th May 20235:07 pmRNSHolding(s) in Company
3rd May 20237:00 amRNSNotice of Results and Investor Presentation
2nd May 20234:13 pmRNSExercise of Options, Issue of Equity & TVR
14th Apr 20234:38 pmRNSHolding(s) in Company
13th Mar 20237:30 amRNSNo Exposure to Silicon Valley Bank
31st Jan 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSAppointment of Independent Non-Executive Director
5th Jan 20237:00 amRNSExercise of Options, Director/PDMR Dealing & TVR
22nd Dec 20227:00 amRNSContract Extension with Leading CRO
30th Nov 20225:48 pmRNSHolding(s) in Company
12th Oct 20227:00 amRNSExercise of Options, Issue of Equity and TVR
27th Sep 20227:01 amRNSHalf-year Report
27th Sep 20227:00 amRNSSettlement of Historical Licence Dispute
13th Sep 20227:00 amRNSNotice of Results and Investor Presentation
9th Sep 20223:49 pmRNSHolding(s) in Company
2nd Sep 20227:00 amRNS$12m five-year agreement with Leading CRO
4th Aug 20227:00 amRNSHalf Year Trading Update
29th Jun 20225:03 pmRNSHolding(s) in Company
9th Jun 20224:01 pmRNSResult of AGM
20th May 20224:31 pmRNSHolding(s) in Company
17th May 20227:00 amRNSNotice of AGM & Posting of Annual Report
3rd May 202212:00 pmRNSHolding(s) in Company
3rd May 20227:00 amRNSEuropean Medicines Agency Research Grant
26th Apr 20224:40 pmRNSSecond Price Monitoring Extn
26th Apr 20224:35 pmRNSPrice Monitoring Extension
26th Apr 202210:15 amRNSEarn Outs and Deferred Payments
26th Apr 20229:54 amRNSFinal Results
26th Apr 20227:00 amRNSAnnouncement re: full year results
20th Apr 20229:05 amRNSNotice of Results & Investor Presentation
15th Mar 20221:49 pmRNSGrant of PDMR Options
14th Mar 20225:29 pmRNSExercise of Options, Issue of Equity and TVR
14th Mar 202211:22 amRNSHolding(s) in Company
22nd Feb 202210:15 amRNSHolding(s) in Company
4th Feb 20228:08 amRNSDirector/PDMR Shareholding
26th Jan 20227:00 amRNSTrading Update
11th Jan 20227:00 amRNSAppointment of Joint Broker
21st Dec 20217:00 amRNSH2 China Market Update
13th Dec 20214:55 pmRNSHolding(s) in Company
22nd Nov 20212:33 pmRNSHolding(s) in Company
22nd Nov 20217:00 amRNSNew In Silico Software Release
11th Oct 20213:15 pmRNSDirector/PDMR Shareholding
29th Sep 202110:34 amRNSHolding(s) in Company
29th Sep 20217:00 amRNSDirectorate Change
28th Sep 20217:00 amRNSGrant of PDMR Options
27th Sep 20217:00 amRNSHalf-year Report
14th Sep 20217:00 amRNSNotice of Results and Investor Presentation
14th Sep 20217:00 amRNSExercise of Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.